Exercise for the mitigation of cancer therapy-related cardiac dysfunction in breast cancer patients treated with anthracyclines: a systematic review and meta-analysis

Structured exercise and cardiac outcomes during anthracycline or anti-HER2 therapy in breast cancer: systematic review and meta-analysis of randomized trials

NEUROHORMONAL MODULATION FOR THE PREVENTION OF ANTHRACYCLINE-INDUCED CARDIAC DYSFUNCTION IN PATIENTS WITH BREAST CANCER: A SYSTEMATIC REVIEW AND META-ANALYSIS OF RANDOMISED CONTROLLED TRIALS

Anthracycline-induced cardiac dysfunction (AICD) is cardiac injury associated with potentially cardiotoxic anthracycline therapy, and remains a significant complication for breast cancer patients. Neurohormonal modulation, a therapeutic strategy used primarily in heart failure, including renin–angiotensin system...

MODERN STRATEGIES FOR EARLY DETECTION OF CANCER THERAPY-RELATED CARDIAC DYSFUNCTION: A SYSTEMATIC REVIEW OF RANDOMIZED CONTROLLED TRIALS

Its use facilitates early detection of subclinical dysfunction and, in selected settings, may improve preservation of left ventricular function; however, a long-term benefit has not been established.

Biomarker and Imaging-Guided Cardioprotection for the Prevention of Anthracycline-Induced Cardiotoxicity: A Systematic Review and Meta-Analysis of Randomized Controlled Trials

Biomarker- and imaging-guided cardioprotective strategies were seen to be implementable and clinically beneficial for the early detection of anthracycline-associated early cardiotoxicity and substantially reduce the risk of CTRCD.

Comorbidity Burden and Cumulative Anti-HER2 Exposure Associated with Cardiac Dysfunction in Breast Cancer: A Real-World Cardio-Oncology Cohort

Background: Cancer-therapy-related cardiac dysfunction (CTRCD) remains an important complication of human epidermal growth factor receptor 2 (HER2)-targeted therapy in patients with breast cancer. Although conventional cardiovascular risk factors and serial cardiac imaging are routinely incorporated into cardio-oncolog...

Cardiac monitoring and incidence of cardiotoxicity cardiomyopathy among breast cancer patients undergoing anthracycline regimen chemotherapy: insight from a single centre study

Anthracyclines remain a cornerstone of breast cancer therapy but carry a significant risk of cancer therapy-related cardiac dysfunction (CTRCD). This study evaluates the incidence of CTRCD in an Indonesian setting using the latest 2022 ESC Cardio-Oncology guidelines, focusing on subclinical markers such as high-s...